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Abstract
Xenotransplantation, the transfer of cells, tissues or organs between species, has 
the potential to overcome the critical need for organs to treat patients. One major 
barrier in the widespread application of xenotransplantation in the clinic is the 
overwhelming rejection response that occurs when non-human organs encounter 
the human immune system. Recent progress in developing new and better genome 
engineering tools now allows the genetic engineering of genes and pathways in 
non-human animals to overcome the human rejection response and provide an 
unlimited supply of rejection-free organs. In this review, the benefits and draw-
backs of various genome engineering protocols, and examples of their application 
in xenotransplantation, are discussed.
Keywords: xenotransplantation, xenoantigen, transgene, gene targeting,  
gene editing, homologous recombination
1. Introduction
According to the Organ Procurement and Transplantation Network, there are 
currently over 110,000 patients on the waiting list for organ transplants. Over the 
past 50 years, therapeutic advances and improvements in surgical techniques have 
increased the number of patients who could survive and benefit from organ trans-
plantation. Unfortunately, the number of organs available through donation has not 
changed significantly. Thus, there is a growing disparity between organ supply and 
demand. Although efforts to enlarge the human donor pool have improved organ 
availability, even a massive expansion in organ donation would not ensure that a 
compatible organ would be available when and where necessary for a patient in 
need. Therefore, other alternatives besides expanded human donation are required.
A variety of efforts are making substantial progress in addressing the lack of organs. 
One area of research that is rapidly approaching clinical reality is xenotransplantation, 
the use of animal tissues and organs to treat patients [1]. Aside from the potential for 
creating an unlimited supply of organs, recent advancements in genome engineering 
technologies allows the genetic modification of animals to produce donor organs which 
are less prone to rejection for xenotransplantation in human patients.
2. History
Xenotransplantation experiments were described as early as the seventeenth-
century [2], with sporadic attempts made to transplant a variety of animal tissues and 
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organs into patients throughout the nineteenth and early twentieth centuries [3–7]. 
After World War II, organ transplantation from living humans was considered too 
high risk, and cadaveric organs were insufficient in both quality and number to meet 
clinical needs. Development of immunosuppressive drugs suggested the possibility 
that organs from more closely-related mammals could potentially be used in humans. 
As a consequence, xenotransplantation efforts shifted to the use of organs from pri-
mates in human patients. In the 1960s, experiments by Reemstma et al. [8, 9], Hardy 
et al. [10], and Starzl et al. [11, 12] showed that while it was technically possible to 
transplant animal organs into humans, there were still too many clinical challenges at 
that time for the approach to be viable. More research was required to understand and 
overcome the barriers to the practical application of xenotransplantation in humans.
One of the major advances in xenotransplantation research in the past few 
decades has been the focus on the use of pigs as donors [13]. This was based, in part, 
on purely practical considerations. Unlike primates, pigs are an agricultural species 
for which large scale breeding is well-established. In addition, the evolutionary dis-
tance between humans and pigs reduces the risk of transmission of zoonoses from 
pig organs to patients compared with primate organs. Most importantly, the use of 
porcine organs does not present the same ethical barriers as the use of non-human 
primate organs [14].
Although the anatomy and physiology of pig organs is closely analogous to 
that of humans, the advantages of porcine organ production and availability do 
not address the critical issue of incompatibilities of non-human tissues and organs 
with the human immune system [15]. Significant advancements have been made 
in recent years in understanding the molecular mechanisms of xenorejection 
responses, and a variety of genetic modifications have been made to overcome these 
mechanisms. Experiments transplanting pig organs into non-human primates have 
demonstrated a progressive improvement in organ survival and function as new 
genetics and drug regimens have been implemented [16]. The FDA is currently 
developing guidelines for clinical xenotransplantation [17], and efforts to initiate 
clinical trials in the near term have been announced [18].
3. Immunity and xenotransplantation
The immune system is designed to recognize and eliminate harmful pathogens, 
while remaining unresponsive to host cells and beneficial microbes. The immune 
system can be divided into innate and adaptive responses, an interdependent set of 
activities which both contribute to immunity. The innate response is more immedi-
ate, broadly recognizing conserved microbial elements, such as cell wall polysac-
charides, and activating a variety of cell types which attack the invading pathogens 
[19]. The adaptive immune response, which is typically initiated by innate response 
mechanisms, leads to more precise antigen-specific antibodies and immune cells 
that continue to control and eliminate pathogens. In addition, the adaptive response 
creates long-lasting immune “memory” for rapid and specific protection against 
future infections, as demonstrated by vaccines [20].
Despite being described as separate systems, the innate and adaptive immune 
responses are highly interdependent and create a layered set of defenses with 
increasing specificity for pathogens over time [21]. Under normal circumstances, 
any individual function may not eliminate a given target with 100% efficiency, 
but when used together in a redundant fashion can prevent nearly all infection. 
Although the specificity of the immune response indirectly helps to avoid recogni-
tion of host tissues, additional tolerance mechanisms are required to restrain the 
immune system to prevent autoreactivity. Disruptions of the balance between 
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immunity and tolerance can lead to the immune system destroying host tissues 
(autoimmunity) or allowing repeated severe infections (immunodeficiency) [22].
The transplantation of foreign cells or tissues into a human host can trigger 
a hostile response from the immune system, leading to immune rejection. The 
extraordinary precision of the immune system can distinguish even minor dif-
ferences between donor and recipient, so that even organs from closely related 
donors may be rejected. Although immunosuppressive drugs can reduce the chance 
of rejection of human donor organs, the massive amount of immunogenic mate-
rial found in a whole organ presents an ongoing risk which requires monitoring. 
Because of the greater genetic differences between pigs and humans, the vigor of 
the rejection response is much stronger than occurs between human donors and 
recipients, requiring more and different solutions.
4. Genome engineering and xenotransplantation
A major advantage in using pigs for xenotransplantation is the potential to 
manipulate the porcine genome to create donor organs that are more compatible 
for human patients. However, the scope of the engineering challenge in xenotrans-
plantation is extremely large, involving a variety of genes and pathways. With so 
many potential targets for genetic modification, an assortment of different genome 
engineering strategies have been applied, including editing or deletion of porcine 
genes and insertion of human or engineered genes. Because of the great diversity 
of genome modification efforts being carried out in xenotransplantation research, 
representative approaches will be highlighted here as examples of the general types 
of the engineering strategies being employed.
Historically, mice have been subject to more and different genetic modifications 
than any other mammalian species, and many of the protocols described here were 
first developed in mice. Aside from their well-established and convenient hus-
bandry, small size, and rapid generation times, mice also have a variety of tech-
nological advantages for genome manipulation and production. Although genetic 
modification has been demonstrated for multiple agricultural species, including 
pigs, the scale and complexity possible with mice has, until recently, not been avail-
able for pigs [23].
One advantage for the creation of mice with multiple genetic modifications is 
the availability of embryonic stem (ES) cells, which can be cultured in vitro for 
many generations and subject to repeated transfections and selections without loss 
of competence for production of viable mice [24]. By contrast, pig ES cells have 
been much more difficult to create, and have not been routinely used for genetic 
manipulation and production of animals [25]. Cloning of genetically-modified 
pigs has required use of primary cells, typically fetal, which can be passaged only a 
short time in vitro before losing their competence to produce viable embryos [26]. 
Therefore, the complex multi-site modifications and selections used in mice are not 
accessible for use in pigs.
Mouse ES cells not only allow more straightforward and efficient genome 
engineering, but also facilitate large scale production of cloned mice. The mouse 
ES cells typically employed for genetic modification can be injected into very early 
stage embryos (blastocysts) and will aggressively populate the inner cell mass, 
creating viable chimeric mice which are almost entirely ES-cell derived. Since the 
ES cells will also contribute to the germ cells of the chimeric mice, the progeny 
will be highly likely to receive the genetic modifications made to the ES cells [27]. 
Without readily available porcine ES cells, pig cloning instead relies upon somatic 
cell nuclear transfer (SCNT), similar to the protocols used to create the sheep 
Genetic Engineering
4
“Dolly”. In this approach, pig oocyte nuclei are replaced with nuclei from the modi-
fied primary pig cells, and embryonic development stimulated electrochemically. 
The embryos are transferred to female surrogates and allowed to develop. The level 
of complexity and effort involved leads to lower efficiencies and higher costs for 
porcine SCNT relative to mouse ES cell cloning. Additionally, the size and scale of 
the facilities required for pig cloning is significantly greater compared with mouse 
cloning, further limiting availability [28].
In the following sections, different types of gene modifications are described with 
examples of their application in porcine genome engineering for xenotransplantation.
5. Gene deletions
As mentioned above, porcine cells produce molecules which are rapidly recog-
nized by the human immune system and rejected. One straightforward approach to 
engineering the pig would be to simply eliminate the genes encoding reactive genes 
by either disrupting or removing the coding sequence. Several of the technical 
routes which can be employed to accomplish this are discussed below.
5.1 Gene knockout
Gene knockout (KO) approaches developed for use in mouse ES cells gener-
ally rely upon homologous recombination to replace a region of genomic DNA 
with a heterologous DNA sequence, which interrupts the function of the target 
gene [29]. To accomplish this, a DNA vector is generated with the heterologous 
DNA flanked on either side by sequences identical to regions flanking the genomic 
region to be eliminated. When introduced into mouse ES cells, the flanking 
sequences of the DNA vector first align with the cognate regions of the genome on 
either side of the target gene, after which the homologous recombination machin-
ery replaces the genomic target with the heterologous DNA vector sequence found 
between the flanking sequences.
Because homologous recombination occurs at a relatively low rate, in order to 
identify properly targeted cells within the larger cell population, it is common to 
include a gene in the heterologous DNA to be inserted into the genome, which, once 
properly inserted, allows selection of the desired cells. For example, genes which 
confer resistance to drugs which kill mammalian cells (neomycin hygromycin or 
puromycin resistance), or genes encoding molecules that enable cells to be isolated 
via flow cytometry (green fluorescent protein or novel cell surface markers), allow 
isolation of even extremely rare targeted cells from a large mixed population [30].
The use of gene KO approaches was one of the earliest successes in pig genetic 
modification for xenotransplantation [31]. The porcine genome encodes proteins 
that can be substantially different from their human counterparts, or that carry 
additional modifications which are not present in humans and can induce immune 
responses. These molecules are collectively referred to as “xenoantigens” [32]. 
Some of the most reactive of these targets are carbohydrate molecules found as 
post-translational modifications to proteins observed in pig, but not human, cells. 
Human serum can contain high levels of pre-existing antibodies specific for these 
porcine-specific glycan epitopes, leading to the destruction of pig cells expressing 
these molecules through antibody-dependent cell-mediated cytotoxicity (ADCC) 
or complement-dependent cytotoxicity (CDC) mechanisms [33]. It is not entirely 
clear why human serum carries antibodies to these particular carbohydrates; one 
proposal is that the xenoantigens are related to glycans found in the cell walls of 
pathogens, others suggest that the human dietary consumption of pork causes 
5Genome Engineering for Xenotransplantation
DOI: http://dx.doi.org/10.5772/intechopen.84782
antibody generation to the porcine-specific molecules [34]. Because the novel 
carbohydrate structures are created by specific glycosylation enzymes, it is possible 
to eliminate the gene responsible for the enzymatic activity and prevent the xenoan-
tigen from being expressed by pig cells.
The GGTA1 gene encodes the enzyme responsible for creating the highly reactive 
glycan Gal alpha (1,3) Gal epitope in pigs [35]. The KO of the GGTA1 gene is one of 
the earliest genetic modifications of pigs for application in xenotransplantation, and 
resulted in greatly reduced human antibody recognition of porcine cells [36, 37]. 
However, ablation of the GGTA1 gene alone did not completely eliminate porcine cell 
recognition by human serum antibodies. The enzymes responsible for other xenoanti-
gens, such as CMAH (cytidine monophosphate-N-acetylneuraminic acid hydroxylase 
critical for Neu5Gc biosynthesis) and B4GALNT2 (beta 1,4 N-acetylgalactosaminyltran
sferase), have been identified as sources of porcine-specific epitopes bound by antibod-
ies found in human serum. In each case, the deletion of the gene responsible for creating 
the specific glycan leads to greatly decreased recognition of porcine cells by antibodies 
in human serum, and reduction in complement-mediated destruction [38, 39].
Another subset of xenoantigens is the swine leukocyte antigens (SLA), the 
physical and functional equivalent of the human leukocyte antigens (HLA) [40]. 
Much like the case for human HLA, the SLA genes are highly diverse and individual 
patients will have a variable level of cross-reactive antibodies in their serum for 
a given set of SLA genes [41]. Although typing of patients and porcine donors to 
find the best HLA-SLA matches would be similar to the current system used for 
determining allotransplant cross-reactivity [42], use of gene targeting or editing 
technologies could easily eliminate the genes encoding SLA entirely. However, unlike 
the glycan epitopes described above, the SLA have a critical role in antigen presenta-
tion as part of the immune response, and thus the deletion of SLA could create risks 
of immune deficiencies that outweigh their risks as xenoantigens. Instead, alternate 
approaches seek to create engineered SLA proteins lacking the epitopes responsible 
for the immunogenicity while maintaining their antigen presentation functions [43].
5.2 Gene editing
The ease and efficiency of creating gene KO has improved recently through the 
use of engineered molecules to create genome disruptions in a process referred to as 
“gene editing”. These novel molecules can be designed to generate double-strand DNA 
breaks at virtually any chosen genomic site in situ. Cellular machinery closely surveils 
the genome for double-strand breaks which are then recognized and often repaired by 
non-homologous end joining (NHEJ). Because NHEJ relies upon small single-strand 
overlaps at the ends of a break, the repair may be imprecise and, if within a coding 
region, can lead to frame shift mutations which inactivate the gene [44].
The most prominent of these novel tools for gene editing are Zinc Finger Nucleases 
(ZFN), Transcription Activator-Like Effector Nuclease (TALEN) and Clustered 
Regularly Interspaced Short Palindromic Repeats (CRISPR), each of which consists 
of two regions: a sequence-specific DNA binding domain and an enzymatic function 
that creates a double-strand break in the target DNA [45–47]. For ZFN and TALEN, 
the synthetic DNA binding domain is created by repetitive protein modules which can 
be joined combinatorially to recognize a particular DNA sequence. Both approaches, 
while successful, require a significant investment of time and resources to identify 
functional molecules. CRISPR, like ZFN and TALEN, has the ability to generate 
double-strand DNA breaks, however, the DNA binding domain relies upon RNA 
base-pairing with target DNA for its precision. The use of an RNA to guide specificity 
greatly improves the speed and efficiency in identifying optimal molecules at a much 
lower cost, which has led to its rapid adoption in genome engineering [48, 49].
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The use of CRISPR for the rapid modification of the pig genome was recently 
demonstrated with the ablation of porcine endogenous retroviral (PERV) 
sequences. The pig genome carries 25 or more copies of these gamma retroviral 
sequences, which are transmitted from parent to offspring through inheritance. 
Application of CRISPR was able to eliminate the PERV sequences from the genome 
of porcine cells [50]. Although the potential risk of infectious disease from porcine 
organs caused by PERV sequences in xenotransplantation is debatable, the results 
show the ability of CRISPR to target multiple, homologous loci throughout the 
genome. A key question that has arisen regarding large scale CRISPR targeting at 
multiple genomic sites is whether significant numbers of off-target double-stranded 
breaks were introduced, which may create unexpected mutations in the resulting 
pigs [51]. Nonetheless, the ease of use of CRISPR has resulted in widespread adop-
tion for genome engineering in xenotransplantation.
Gene deletion has been instrumental in the advancement of xenotransplanta-
tion, however, there are limitations to its application; the genes of interest must be 
non-essential to pig viability, development, fertility and, most importantly, organ 
function. The number of distinct loci to be targeted is also a serious consideration, 
since independently-assorting alleles will be challenging to breed together in a 
reasonable timeframe. To address these concerns, additional engineering strategies 
are required as discussed below.
6. Gene insertions
Gene KO and editing techniques have been used for ablation of xenoantigen 
genes but do not address the need to express human or synthetic genes in pig cells 
and organs. Unlike gene deletions, gene insertions require heterologous DNA to 
be introduced into the genome in a manner that allows subsequent expression of 
the gene(s) encoded by the inserted DNA. Because they are being transferred into 
the genome from another source, these novel genes are referred to as “transgenes” 
(TG), whether they are derived from natural or synthetic sequences. The general 
approaches to introduce TG into the genome are detailed below.
6.1 Random integrant TG
One of the earliest types of genetic modification described in mammals was 
insertion of DNA into the target genome by random integration. After transfection 
of DNA into nearly all mammalian cells, some portion of the heterologous DNA 
can be found incorporated at random sites in the genome [52]. The precise process 
for this is unclear, but presumably is a result of aberrant repair mechanisms. One 
hypothesis is that endogenous NHEJ machinery recognizes breaks in the genome 
and fortuitously utilizes the relatively higher concentration of the heterologous 
DNA vector sequences to repair the break [53], resulting in the insertion of the TG 
into the genome.
Agricultural species, including pig, were some of the earliest TG animals 
described, establishing the utility of this approach [54]. For xenotransplantation, 
several of the initial TG approaches focused on inhibiting human antibody-
mediated damage of porcine organs. The binding of human antibodies to porcine 
cells leads to complement pathway activation and subsequent cell ablation [55]. The 
complement function is controlled by several proteins, such as CD46, CD55 and 
CD59, referred to as complement regulatory proteins (CRPs). The CRPs are broadly 
expressed on many different cell types to prevent harm from complement activity 
by raising the threshold of antibody binding required for complement pathway 
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induction [56]. The transgenic expression of human CRPs in pigs appears to over-
come human complement activity, and may have the potential to reduce, or even 
eliminate, the need for xenoantigen KOs. By placing the human CRP TGs under the 
control of strong gene expression elements, the CRP protein levels on the porcine 
cells can be much higher than CRP levels on normal human cells, further increasing 
resistance to complement-mediated destruction [57].
Pig lineages developed by multiple labs have been engineered to express human 
CRPs, individually or in combination. In most cases, the porcine cells appeared 
to be more resistant to complement-mediated destruction, and organs from TG 
animals survived longer in xenotransplant experiments in non-human primates 
[58–60]. Because each of the CRPs control a different part of the complement 
pathway, the use of multiple human TGs was more effective in protecting cells from 
complement-mediated destruction than individual TGs [61]. Together with the 
removal of key xenoantigens, the expression of human CRPs by porcine cells has 
greatly reduced the effects of human serum antibodies on xenografts.
Because random insertion of DNA does not require homologous recombination, 
it is relatively rapid and efficient to produce transgenic animals [62]. The process is 
so efficient that the selection methods that are critical for gene KO described above 
are often unnecessary for TG. Despite the speed and ease of generation, random 
integration of TGs has several drawbacks. Variabilities in genome structure can 
affect the expression level of genes inserted at distinct chromosomal regions, such 
that identical TGs may express at very different levels depending upon their specific 
location [63]. Furthermore, multiple copies of a given TG may be inserted into the 
genome at a single site, creating concatenated repeats which can be unstable and 
yield variable expression levels [64]. Random TG insertion may occur within or 
near endogenous genes and alter or inactivate their function, leading to tumorigen-
esis, instability or even lethality [65].
6.2 Homologous recombination
The development of techniques for precise gene KO by homologous recombina-
tion has been adapted for site-specific gene insertion or gene knock-in (KI). Similar 
to the KO vectors described above, the gene to be introduced is flanked by DNA 
sequences that are identical to regions of the genome to be targeted. After introduc-
tion of the heterologous DNA vector, the regions of DNA sequence identity are 
aligned with the target genome sequence, after which the homologous recombina-
tion machinery catalyzes reactions which swap the endogenous genomic DNA with 
the heterologous DNA within the construct. If the recombination event occurs 
with high fidelity, the gene of interest will functionally replace the gene that was 
removed [24]. Similar to gene KO, this approach is much less efficient than random 
TG integration. Therefore, vectors carrying the TG are often designed to incorporate 
selectable markers, similar to those used for gene KO, to allow the identification of 
cells carrying the desired TG in the genome. In this case, both targeted and randomly 
integrated TGs may be selected, requiring additional assays, such as PCR or Southern 
blotting, to distinguish between sequence-specific and random insertion events [30].
As described above for gene KO, specific targeting is more efficient in murine ES 
cells, which express the enzymatic machinery necessary for homologous recombina-
tion, than is currently possible for pig primary cells. Insertion of heterologous DNA 
into the mammalian genome is believed to be driven by endogenous DNA repair 
mechanisms, presumably in response to DNA breaks, whether randomly via NHEJ, 
or specifically via homologous recombination [66]. The deliberate introduction of 
double-stranded DNA breaks at the desired integration site should therefore improve 
the efficiency of heterologous DNA insertion by activating and recruiting the cellular 
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repair machinery. Application of ZFN, TALEN and CRISPR technologies have shown 
that homologous recombination efficiencies are improved when one or more double-
strand DNA breaks are introduced into the genome at the desired site of insertion 
[67] with CRISPR exhibiting bi-allelic targeting rates as high as 90% [68]. The use of 
these more advanced genome engineering tools has greatly improved the rates and 
specificity of both gene deletion and gene insertion in genomes.
Gene insertion by homologous recombination for xenotransplantation has not 
advanced as rapidly as other approaches, in part due to the challenges of using primary 
porcine cells, for which the efficiencies can be extremely low, particularly with large 
DNA constructs. Use of improved genome engineering tools with increased target-
ing efficiencies have already been applied in pig and will continue to grow in impact 
[69]. However, even with improved efficiencies of gene insertion, breeding pigs with 
multiple, independently segregating loci is challenging. The number of litters required 
to produce animals bearing all of the genetic modifications greatly increases with each 
additional locus, which can be impractical for large animals such as pigs. Therefore, 
the ability to insert the maximal amount of genetic information into the genome in the 
minimal number of steps, as discussed below, is highly valuable.
6.3 Multigenic insertion
The most straightforward example of multigenic targeting at a single site takes 
advantage of the observation that multiple DNA vectors co-transfected into cells 
will tend to insert together at a given genome site. This approach was used suc-
cessfully to simultaneously introduce as many as five large transgenes in a single 
step into porcine cells [70]. Although difficulties in producing mature cloned pigs 
limited the study to animals with fewer integrated genes, the study demonstrated 
the feasibility of rapidly making animals with multiple TG.
Another, relatively less complicated, way to introduce multiple TG is to gener-
ate large DNA constructs bearing multiple TGs for integration at random into the 
genome [71]. This greatly reduces the complexity of screening, while increasing 
the efficiency of insertion, but still relies upon random integrants which can have 
variable TG copy numbers and expression levels.
Multiple genomic regions have been defined, such as Rosa26, which allow expression 
of heterologous genes at similar levels regardless of cell type. These “safe harbor” regions 
are believed to have a chromatin structure that is more easily accessible to the gene 
expression machinery, regardless of cell type. Targeting at porcine homologs of murine 
safe harbor sites such as Rosa26 has been described and demonstrates the utility of this 
approach [70, 72]. On a practical level, the use of safe harbor sites yields more reproduc-
ible gene expression than random TG insertions, so fewer lineages are required to select 
animals with desired TG levels. Furthermore, the defined location and copy number of 
TG inserted at a safe harbor site makes breeding and genotyping more straightforward, 
and is expected to provide a less complicated regulatory pathway for clinical use.
As DNA synthesis and assembly has improved, increasingly large DNA con-
structs encoding a variety of TG are possible, however, as the size of the DNA 
increases, the rate of insertion decreases. Considering the lower insertion rates 
observed for large animals such as pig, alternate approaches are necessary to incor-
porate larger DNAs into the genome.
6.4 Site-specific recombination
Bacteriophage- and yeast-derived site-specific recombinases are, as the name 
suggests, proteins which catalyze recombination between two specific DNA recogni-
tion sites, small (<50 base pair) sequences that are unique to the recombinase being 
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used. The recombination event is highly efficient, in some cases eliminating the 
need for selection genes, and allowing large DNA constructs to be inserted at a much 
higher frequency than possible for homologous recombination [73].
One limitation for the use of site-specific recombination is the need for a recog-
nition sequence to be present in the target genome at the desired locus. This requires 
a preceding step in which the recognition site is engineered into the genome using 
less efficient homologous recombination. Therefore, the gain in efficiency for 
introduction of large DNA constructs may be offset by the need for insertion of the 
recombinase recognition site into the genome. Despite this constraint, the potential 
for site-specific recombination into a defined locus has been demonstrated in pigs 
[70] and provides a route for more rapid complex genetic modifications.
7. Future needs
The advancements in genome engineering, both in general and in their application 
to xenotransplantation, have been significant, but many needs remain to be addressed. 
As new genome engineering tools are identified and further refined, improvement of 
targeting efficiencies will allow more sophisticated modifications of the pig genome. 
Ideally, the pig genome will become as readily manipulated as the mouse, allowing 
researchers to further leverage approaches shown to be effective in murine models.
One major technological difference in the genetic modification of mice and pigs 
(and many other mammalian species) is the lack of ES cells possessing significant 
rates of homologous recombination that can be grown in culture for extended peri-
ods and subjected to multiple manipulations without losing the ability to produce 
viable pigs. Efforts to identify natural or induced pluripotent stem cells (iPSC) suit-
able for these purposes have been described, but have yet to demonstrate practical 
application for porcine genome engineering [74]. Ongoing work will be required to 
identify and validate cells which meet these needs.
The function of the TGs themselves can also be further improved. The majority of TG 
constructs used in pigs have used constitutive promoters to drive high level expression 
of the proteins encoded by the TGs. In some cases, such as CRPs, this approach may be 
useful, however, overexpression of TGs which inhibit critical immune processes may cre-
ate risks of immune deficiency and infections. For this reason, use of expression control 
elements which can turn on and off TG activity is of increasing interest in xenotransplan-
tation. There are multiple examples of inducible promoters employed in mice which can 
be controlled by exogenously applied small molecules (such as the tetracycline repressor 
system), or by endogenous signals (such as promoters for innate immune response genes) 
[75]. Advanced DNA synthesis and assembly methods also allow synthetic biology 
approaches to create novel signaling pathways and networks not present in nature.
Immune tolerance is another very active area in xenotransplantation research. As 
the molecular mechanisms controlling the balance between immunity and tolerance 
are further elucidated, manipulation of the human immune system itself to specifi-
cally reduce or eliminate responses to porcine targets, while leaving intact immunity 
to infectious diseases, will help overcome xenorejection. Multiple approaches are 
currently being tested and genome targets identified to encourage human immune 
tolerance of porcine cells and tissues [76, 77].
8. Conclusions
The speed and ease of genome engineering technologies has helped to overcome 
many of the limitations for the use of pig organs for xenotransplantation. Despite recent 
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achievements, a key question remains: which combination of genetic modifications is 
most critical to make a pig organ useful for xenotransplantation? Ongoing experiments 
seek to address this question, but the answers are likely to be complex and dependent 
upon the type of organ, the specific immune mechanisms involved, and perhaps other 
factors that are not yet defined. It is very likely that the first set of genetic modifications 
of pigs used for xenotransplantation in humans will not be the final set, as the under-
standing of the mechanisms of xenorejection increases and better strategies developed 
to influence the human immune response. Continuing progress in genome engineering 
technologies of pigs will allow the creation of the more complex modifications neces-
sary to meet these demands. Although much remains to be done, it is clear that given the 
current rate of progress, overcoming the crisis of human organ shortage with unlimited 
rejection-free porcine organs is rapidly growing closer to reality.
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